Skip to main content
TipRanks
Go Ultimate75% OFF

Theralase Technologies (TTX) Q1 2025 Earnings Report

1 Followers

DE:TTX Q1 2025 EPS Results

Actual EPS
EUR 0.00
Consensus EPS
EUR 0.00
Beat/Miss
Missed by -EUR 0.00
One Year Ago EPS
EUR 0.00

DE:TTX Q1 2025 Revenue Results

Actual Revenue
EUR 57.96K
Expected Revenue
EUR 127.12K
Beat/Miss
Missed by -EUR 69.16K
YoY Revenue Growth
-48.06%

Earnings Announcement Details

Quarter
Q1 2025
Date
05/29/2025
Time
After Close
Conference Call
Thursday, May 29, 2025
DE:TTX Upcoming Earnings

Theralase Technologies's next earnings date is estimated for December 2, 2026, based on past reporting schedules.

Q1 2025 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q1 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2025 Earnings Call Summary

Q1 2025
Earnings Call Date:May 29, 2025|% Change Since:-0.93%|
Earnings Call Sentiment|Neutral

The earnings call reflects a company at a pivotal moment, with significant progress in clinical studies and plans for expansion into multiple high-value indications. While the financials show a decline in revenue and increased expenses, the strategic initiatives and successful capital raising efforts position Theralase for future growth.

Company Guidance

During the call, Theralase Technologies provided guidance on several metrics and strategic initiatives. The company is on track to complete enrollment in its registrational bladder cancer study by summer 2025, with a 15-month patient follow-up expected to conclude by the third quarter of 2026. Theralase plans to file a New Drug Application with Health Canada and the FDA in the fourth quarter of 2026, aiming for marketing approval in early 2027. Financially, the company reported nominal revenues of $91,000 for Q1 2025, largely from its Cool Laser Therapy systems, down from $175,000 the previous year. Despite a net loss of $1.47 million, Theralase has raised nearly $7.5 million over the past 24 months through private placements. The company is exploring a potential U.S. uplist and institutional financing, which could enhance its capital position and broaden its investor base. Additionally, Theralase is advancing a pipeline that includes nine new indications, with plans for Phase I/II clinical studies in 2026. The company highlighted a 62% complete response rate in its bladder cancer study, emphasizing the safety and efficacy of its Ruvidar treatment.

  • Completion of Bladder Cancer Study EnrollmentTheralase is on track to complete enrollment in a critical bladder cancer study by the summer of 2025, marking a significant milestone in their clinical development.
  • Expansion into New Oncology and Virology IndicationsTheralase plans to expand its pipeline into 9 high-value indications, including brain cancer, lung cancer, pancreatic cancer, and Herpes Simplex virus, positioning the company for growth in these areas.
  • Strong Interim Clinical ResultsStudy II for bladder cancer achieved a 62% complete response rate at any time, with no serious adverse events related to the treatment, indicating a promising safety and efficacy profile.
  • Potential U.S. Listing and Institutional RaiseTheralase is exploring a U.S. institutional raise and listing, which could broaden the investor base, improve stock liquidity, and provide necessary capital for pipeline expansion.
  • Successful Capital RaisingTheralase successfully closed private placements totaling $730,000 in the first and second quarters of 2025, contributing to nearly $7.5 million raised over the past 24 months.

DE:TTX Earnings History

DE:TTX earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Dec 02, 20262026 (Q3)-0.00-0――
Aug 28, 20262026 (Q2)-0.00-0.00025.00% (+0.00)
May 29, 20262026 (Q1)―-0―
May 04, 20262025 (Q4)-0.00-0.00033.33% (+0.00)
Nov 10, 20252025 (Q3)-0.00-0.0000.00% (+0.00)
Aug 26, 20252025 (Q2)-0.00-0.00020.00% (+0.00)
May 29, 20252025 (Q1)-0.00-0.0000.00% (+0.00)
Mar 12, 20252024 (Q4)-0.00-0.000―
Nov 27, 20242024 (Q3)-0.00-0.000―
Aug 12, 20242024 (Q2)-0.00-0.000―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed